Cargando…

The impact of certain underlying comorbidities on the risk of developing hospitalised pneumonia in England

BACKGROUND: UK specific data on the risk of developing hospitalised CAP for patients with underlying comorbidities is lacking. This study compared the likelihood of hospitalised all-cause community acquired pneumonia (CAP) in patients with certain high-risk comorbidities and a comparator group with...

Descripción completa

Detalles Bibliográficos
Autores principales: Campling, J., Jones, D., Chalmers, J. D., Jiang, Q., Vyse, A., Madhava, H., Ellsbury, G., Slack, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788086/
https://www.ncbi.nlm.nih.gov/pubmed/31632897
http://dx.doi.org/10.1186/s41479-019-0063-z
_version_ 1783458422277013504
author Campling, J.
Jones, D.
Chalmers, J. D.
Jiang, Q.
Vyse, A.
Madhava, H.
Ellsbury, G.
Slack, M.
author_facet Campling, J.
Jones, D.
Chalmers, J. D.
Jiang, Q.
Vyse, A.
Madhava, H.
Ellsbury, G.
Slack, M.
author_sort Campling, J.
collection PubMed
description BACKGROUND: UK specific data on the risk of developing hospitalised CAP for patients with underlying comorbidities is lacking. This study compared the likelihood of hospitalised all-cause community acquired pneumonia (CAP) in patients with certain high-risk comorbidities and a comparator group with no known risk factors for pneumococcal disease. METHODS: This retrospective cohort study interrogated data in the Hospital Episodes Statistics (HES) dataset between financial years 2012/13 and 2016/17. In total 3,078,623 patients in England (aged ≥18 years) were linked to their hospitalisation records. This included 2,950,910 individuals with defined risk groups and a comparator group of 127,713 people who had undergone tooth extraction with none of the risk group diagnoses. Risk groups studied were chronic respiratory disease (CRD), chronic heart disease (CHD), chronic liver disease (CLD), chronic kidney disease (CKD), diabetes (DM) and post bone marrow transplant (BMT). The patients were tracked forward from year 0 (2012/13) to Year 3 (2016/17) and all diagnoses of hospitalised CAP were recorded. A Logistic regression model compared odds of developing hospitalised CAP for patients in risk groups compared to healthy controls. The model was simultaneously adjusted for age, sex, strategic heath authority (SHA), index of multiple deprivation (IMD), ethnicity, and comorbidity. To account for differing comorbidity profiles between populations the Charlson Comorbidity Index (CCI) was applied. The model estimated odds ratios (OR) with 95% confidence intervals of developing hospitalised CAP for each specified clinical risk group. RESULTS: Patients within all the risk groups studied were more likely to develop hospitalised CAP than patients in the comparator group. The odds ratios varied between underlying conditions ranging from 1.18 (95% CI 1.13, 1.23) for those with DM to 5.48 (95% CI 5.28, 5.70) for those with CRD. CONCLUSIONS: Individuals with any of 6 pre-defined underlying comorbidities are at significantly increased risk of developing hospitalised CAP compared to those with no underlying comorbid condition. Since the likelihood varies by risk group it should be possible to target patients with each of these underlying comorbidities with the most appropriate preventative measures, including immunisations.
format Online
Article
Text
id pubmed-6788086
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67880862019-10-18 The impact of certain underlying comorbidities on the risk of developing hospitalised pneumonia in England Campling, J. Jones, D. Chalmers, J. D. Jiang, Q. Vyse, A. Madhava, H. Ellsbury, G. Slack, M. Pneumonia (Nathan) Research BACKGROUND: UK specific data on the risk of developing hospitalised CAP for patients with underlying comorbidities is lacking. This study compared the likelihood of hospitalised all-cause community acquired pneumonia (CAP) in patients with certain high-risk comorbidities and a comparator group with no known risk factors for pneumococcal disease. METHODS: This retrospective cohort study interrogated data in the Hospital Episodes Statistics (HES) dataset between financial years 2012/13 and 2016/17. In total 3,078,623 patients in England (aged ≥18 years) were linked to their hospitalisation records. This included 2,950,910 individuals with defined risk groups and a comparator group of 127,713 people who had undergone tooth extraction with none of the risk group diagnoses. Risk groups studied were chronic respiratory disease (CRD), chronic heart disease (CHD), chronic liver disease (CLD), chronic kidney disease (CKD), diabetes (DM) and post bone marrow transplant (BMT). The patients were tracked forward from year 0 (2012/13) to Year 3 (2016/17) and all diagnoses of hospitalised CAP were recorded. A Logistic regression model compared odds of developing hospitalised CAP for patients in risk groups compared to healthy controls. The model was simultaneously adjusted for age, sex, strategic heath authority (SHA), index of multiple deprivation (IMD), ethnicity, and comorbidity. To account for differing comorbidity profiles between populations the Charlson Comorbidity Index (CCI) was applied. The model estimated odds ratios (OR) with 95% confidence intervals of developing hospitalised CAP for each specified clinical risk group. RESULTS: Patients within all the risk groups studied were more likely to develop hospitalised CAP than patients in the comparator group. The odds ratios varied between underlying conditions ranging from 1.18 (95% CI 1.13, 1.23) for those with DM to 5.48 (95% CI 5.28, 5.70) for those with CRD. CONCLUSIONS: Individuals with any of 6 pre-defined underlying comorbidities are at significantly increased risk of developing hospitalised CAP compared to those with no underlying comorbid condition. Since the likelihood varies by risk group it should be possible to target patients with each of these underlying comorbidities with the most appropriate preventative measures, including immunisations. BioMed Central 2019-10-11 /pmc/articles/PMC6788086/ /pubmed/31632897 http://dx.doi.org/10.1186/s41479-019-0063-z Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Campling, J.
Jones, D.
Chalmers, J. D.
Jiang, Q.
Vyse, A.
Madhava, H.
Ellsbury, G.
Slack, M.
The impact of certain underlying comorbidities on the risk of developing hospitalised pneumonia in England
title The impact of certain underlying comorbidities on the risk of developing hospitalised pneumonia in England
title_full The impact of certain underlying comorbidities on the risk of developing hospitalised pneumonia in England
title_fullStr The impact of certain underlying comorbidities on the risk of developing hospitalised pneumonia in England
title_full_unstemmed The impact of certain underlying comorbidities on the risk of developing hospitalised pneumonia in England
title_short The impact of certain underlying comorbidities on the risk of developing hospitalised pneumonia in England
title_sort impact of certain underlying comorbidities on the risk of developing hospitalised pneumonia in england
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788086/
https://www.ncbi.nlm.nih.gov/pubmed/31632897
http://dx.doi.org/10.1186/s41479-019-0063-z
work_keys_str_mv AT camplingj theimpactofcertainunderlyingcomorbiditiesontheriskofdevelopinghospitalisedpneumoniainengland
AT jonesd theimpactofcertainunderlyingcomorbiditiesontheriskofdevelopinghospitalisedpneumoniainengland
AT chalmersjd theimpactofcertainunderlyingcomorbiditiesontheriskofdevelopinghospitalisedpneumoniainengland
AT jiangq theimpactofcertainunderlyingcomorbiditiesontheriskofdevelopinghospitalisedpneumoniainengland
AT vysea theimpactofcertainunderlyingcomorbiditiesontheriskofdevelopinghospitalisedpneumoniainengland
AT madhavah theimpactofcertainunderlyingcomorbiditiesontheriskofdevelopinghospitalisedpneumoniainengland
AT ellsburyg theimpactofcertainunderlyingcomorbiditiesontheriskofdevelopinghospitalisedpneumoniainengland
AT slackm theimpactofcertainunderlyingcomorbiditiesontheriskofdevelopinghospitalisedpneumoniainengland
AT camplingj impactofcertainunderlyingcomorbiditiesontheriskofdevelopinghospitalisedpneumoniainengland
AT jonesd impactofcertainunderlyingcomorbiditiesontheriskofdevelopinghospitalisedpneumoniainengland
AT chalmersjd impactofcertainunderlyingcomorbiditiesontheriskofdevelopinghospitalisedpneumoniainengland
AT jiangq impactofcertainunderlyingcomorbiditiesontheriskofdevelopinghospitalisedpneumoniainengland
AT vysea impactofcertainunderlyingcomorbiditiesontheriskofdevelopinghospitalisedpneumoniainengland
AT madhavah impactofcertainunderlyingcomorbiditiesontheriskofdevelopinghospitalisedpneumoniainengland
AT ellsburyg impactofcertainunderlyingcomorbiditiesontheriskofdevelopinghospitalisedpneumoniainengland
AT slackm impactofcertainunderlyingcomorbiditiesontheriskofdevelopinghospitalisedpneumoniainengland